Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Non-Current Deffered Revenue (2016 - 2018)

Historic Non-Current Deffered Revenue for NovaBay Pharmaceuticals (NBY) over the last 9 years, with Q4 2018 value amounting to $184000.0.

  • NovaBay Pharmaceuticals' Non-Current Deffered Revenue fell 6554.31% to $184000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $184000.0, marking a year-over-year decrease of 6554.31%. This contributed to the annual value of $184000.0 for FY2018, which is 6554.31% down from last year.
  • Latest data reveals that NovaBay Pharmaceuticals reported Non-Current Deffered Revenue of $184000.0 as of Q4 2018, which was down 6554.31% from $213000.0 recorded in Q3 2018.
  • Over the past 5 years, NovaBay Pharmaceuticals' Non-Current Deffered Revenue peaked at $3.1 million during Q1 2016, and registered a low of $184000.0 during Q4 2018.
  • Moreover, its 5-year median value for Non-Current Deffered Revenue was $1.9 million (2016), whereas its average is $1.6 million.
  • Per our database at Business Quant, NovaBay Pharmaceuticals' Non-Current Deffered Revenue skyrocketed by 11986.3% in 2014 and then crashed by 8813.22% in 2018.
  • Over the past 5 years, NovaBay Pharmaceuticals' Non-Current Deffered Revenue (Quarter) stood at $2.0 million in 2014, then grew by 12.4% to $2.2 million in 2015, then fell by 11.65% to $2.0 million in 2016, then tumbled by 73.11% to $534000.0 in 2017, then crashed by 65.54% to $184000.0 in 2018.
  • Its Non-Current Deffered Revenue stands at $184000.0 for Q4 2018, versus $213000.0 for Q3 2018 and $237000.0 for Q2 2018.